Current Report Filing (8-k)
March 10 2023 - 4:44PM
Edgar (US Regulatory)
0001177648false00011776482023-03-102023-03-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of earliest event reported): March 10, 2023 |
ENANTA PHARMACEUTICALS, INC.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware |
001-35839 |
04-3205099 |
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
|
500 Arsenal Street |
|
Watertown, Massachusetts |
|
02472 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
|
Registrant’s Telephone Number, Including Area Code: (617) 607-0800 |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading Symbol(s) |
|
Name of each exchange on which registered
|
Common Stock, par value $0.01 per share |
|
ENTA |
|
Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
On March 10, 2023, Enanta Pharmaceuticals, Inc. reported that less than approximately 5% of its cash and marketable securities are held in operating accounts at Silicon Valley Bank. Its investments in marketable securities are held in custody accounts at an independent institution. Accordingly, there is no material impact on its projected cash runway or operations.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
ENANTA PHARMACEUTICALS, INC. |
|
|
|
|
Date: |
March 10, 2023 |
By: |
/s/ Paul J. Mellett |
|
|
|
Paul J. Mellett Senior Vice President, Finance and Administration and Chief Financial Officer |
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jul 2024 to Aug 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Aug 2023 to Aug 2024